You are here

Article Text

Article menu
Download PDFPDF
Highlights from the literature
Highlights from the literature
  1. Samuel Tribich1,
  2. James Maurice2
  1. 1 Department of Acute Medicine, Whipps Cross University Hospital, London, UK
  2. 2 Department of Gastroenterology, Whipps Cross University Hospital, London, UK
  1. Correspondence to Dr Samuel Tribich, Department of Acute Medicine, Whipps Cross University Hospital, London E11 1NR, UK; samuel.tribich{at}nhs.net

https://doi.org/10.1136/flgastro-2019-101389

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Beta blockers decrease decompensation in cirrhosis

    The PREDESCI trial,1 published in The Lancet, is the first randomised controlled trial (RCT) to evaluate the efficacy of non-selective beta-blockers in the primary prevention of hepatic decompensation in patients with compensated cirrhosis and clinically significant portal hypertension (CSPH).

    Two hundred and one patients with compensated cirrhosis and CSPH (baseline hepatic venous pressure gradient (HVPG) ≥10 mm Hg), no previous decompensation and no high-risk oesophageal varices were recruited. Acute HVPG responders to intravenous propranolol were randomised to propranolol or placebo and non-responders to carvedilol or placebo. The primary endpoint was decompensation (ascites, variceal bleeding or overt encephalopathy) or liver-related death.

    Decompensation or death occurred in 16% (16/100) in the beta-blocker group versus 27% (27/101) in the placebo group (HR 0.51, 95% CI 0.26 to 0.97, p=0.04). This difference was largely attributable to a significant reduction in the incidence of ascites (HR 0.42, 95% CI 0.19 to 0.92, p=0.03). There was a greater reduction in HVPG in the carvedilol group compared to propranolol (16% vs 10%, p=0.036) and no significant reduction in the placebo group.

    The development …

    View Full Text

    Footnotes

    • Contributors The article was jointly written and edited by ST and JM.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; internally peer reviewed.